{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Mitoguazone",
  "nciThesaurus": {
    "casRegistry": "459-86-9",
    "chebiId": "",
    "chemicalFormula": "C5H12N8",
    "definition": "A guanylhydrazone with potential antineoplastic activity. Mitoguazone competitively inhibits S-adenosyl-L-methionine decarboxylase (SAMD), an enzyme involved in the synthesis of polyamines, resulting in decreased proliferation of tumor cells, antimitochondrial effects, and p53-independent apoptosis. Polyamines, specifically spermine and spermidine, are essential for thymidine kinase production, DNA synthesis, and cell proliferation.",
    "fdaUniiCode": "OD5Q0L447W",
    "identifier": "C661",
    "preferredName": "Mitoguazone",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C2076",
      "C2090"
    ],
    "synonyms": [
      "1,1'-((methylethanediylidene)dinitrilo)diguanidine",
      "2,2\"-(methyl-1,2-ethanediylidene)bis[hydrazinecarboximidamide]",
      "DRG-0223",
      "MGBG",
      "MITOGUAZONE",
      "Me-GAG",
      "Methyl GAG",
      "Methyl-G",
      "Methyl-GAG",
      "Methylglyoxal Bisguanylhydrazone",
      "Methylglyoxal bis(amidinohydrazone)",
      "Mitoguazone",
      "Zyrkamine",
      "methylglyoxal bis(guanylhydrazone)",
      "pyruvaldehyde bis(amidinohydrazone)"
    ]
  }
}